By: Brenda Neugent
After a phase III study that showed no reduction in cardiovascular events for those with diabetes, continued trials for the diabetes drug Aleglitazar have been scrapped.
The results were revealed at the 2014 American College of Cardiology Scientific Sessions.
Previous studies had showed reductions in A1c, triglycerides and LDL, or “bad” cholesterol, while raising levels of good cholesterol.
The current phase, however, while revealing a reduction in A1c levels as well as cholesterol, failed to have an impact on cardiovascular events, leading the Swiss drug maker, Roche, to terminate this and all further studies of the drug.
In addition to showing no cardiovascular benefits, the drug – a peroxisome proliferator-activated receptor agonist – has been associated with an increased risk of hypoglycemia, bone fractures, renal abnormalities and cardiovascular.
Drugs in this class have also been linked to an increased risk of cancer.